BRIGHT MINDS BIOSCIENCES INC.

DRUG

Held by 8 specialist biotech funds

High Convergence

8 funds opened new positions. Next phase2 readout (BMB-101): Sep 2025. Short interest: 10.8% of float.

BiotechnologyCEO: Ian McDonaldIPO: 2021Website ↗

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

BRIGHT MINDS BIOSCIENCES INC.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research